Disease · MONDO_0016642

meningioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. meningioma. Diseases, record MONDO_0016642. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016642

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: meningioma; Open Targets
Open Targets ID: MONDO_0016642; Open Targets
Other names: meningioma (disease), meningioma NOS, meningioma NOS (morphologic abnormality), meningioma, benign, no ICD-O subtype (morphologic abnormality), meningiomas (morphologic abnormality); Open Targets
Disease Ontology: DOID:3565; Disease Ontology
MeSH: D008579; MeSH
NCI Thesaurus: C3230; NCI Thesaurus
Orphanet: ORPHA:2495; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 45 drugs, from ClinicalTrials.gov; Open Targets

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MIFEPRISTONE	CHEMBL1276308	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AR-42	CHEMBL191482	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
HYDROXYUREA	CHEMBL467	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
LUTETIUM OXODOTREOTIDE LU-177	CHEMBL4297545	Protein	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ABEMACICLIB	CHEMBL3301610	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 45

See all 45 drugs

Targets71

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	5	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	5	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
EGFR	Epidermal growth factor receptor	4	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
ABL1	Bcr/Abl fusion protein	3	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
SSTR1	Somatostatin receptor	3	Somatostatin receptor 1 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent	Phase 2	https://conductscience.org/library/genes/6751	Drugs and targets

1 to 10 of 71

See all 71 targets

Trials59

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00045110	Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma	Phase 1/2	136	2017-07-13	Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Recurrent Adult Brain Tumor	ERLOTINIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02234050	Trabectedin for Recurrent Grade II/III Meningioma	Phase 2	90	2025-07-10	Recurrent High Grade Meningioma	TRABECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT03558516	Magnesium and Intraoperative Blood Loss in Meningioma Surgery	Phase 3	80	2020-07-13	Meningioma	MAGNESIUM SULFATE	Its record names the disease	ClinicalTrials.gov
NCT00589784	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	Phase 2	50	2016-01-25	CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT01125046	Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas	Phase 2	50	2021-01-22	Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Meningeal Hemangiopericytoma, Adult Papillary Meningioma, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Recurrent Adult Brain Tumor	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02648997	An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma	Phase 2	40	2026-01-26	Meningiomas	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00859040	Monthly SOM230C for Recurrent or Progressive Meningioma	Phase 2	34	2014-05-16	Meningioma	PASIREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT00003590	S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma	Phase 2	29	2012-02-16	Adult Meningioma	HYDROXYUREA	Its record names the disease	ClinicalTrials.gov
NCT03279692	Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma	Phase 2	26	2023-06-06	High Grade Meningioma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00348790	Vatalanib in Treating Patients With Recurrent or Progressive Meningioma	Phase 2	25	2014-10-27	Brain and Central Nervous System Tumors, Sarcoma	VATALANIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 59

See all 59 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Phase 1 Dose Escalation vs Phase 2 Recurrent Malignant Gliomas and Nonprogressive Gbm: serious adverse events	0 of 32	2 of 99	131	NCT00045110	Trial comparisons
Trabectedin vs Local Standard of Care: deaths from any cause	40 of 61	17 of 27	88	NCT02234050	Trial comparisons
Trabectedin vs Local Standard of Care: serious adverse events	26 of 61	4 of 27	88	NCT02234050	Trial comparisons
Group NSS vs Group Mg: Patient Received Intraoperative Packed Red Cell (PRC)	10 of 38	7 of 38	76	NCT03558516	Trial comparisons
Group NSS vs Group Mg: deaths from any cause	0 of 38	0 of 38	76	NCT03558516	Trial comparisons
Group NSS vs Group Mg: serious adverse events	1 of 38	1 of 38	76	NCT03558516	Trial comparisons
Participants With Atypical/Malignant Meningiomas vs Participants With Benign Meningiomas: Response Rate	0 of 18	0 of 16	34	NCT00859040	Trial comparisons
Bevacizumab vs Placebo: serious adverse events	4 of 11	0 of 6	17	NCT00492089	Trial comparisons
Arm A: Bevacizumab vs Crossover Arm B: Placebo Then Bevacizumab: Number of Participants With Response ( > 25% Reduction in T2 Flair) From Baseline to Evaluation at 6 Weeks Post Treatment	5 of 5	6 of 6	11	NCT00492089	Trial comparisons

Papers from its trials27

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38052364	RESULT	1	PubMed
34952528	RESULT	1	PubMed
34824110	RESULT	1	PubMed
34667843	RESULT	1	PubMed
31831982	RESULT	1	PubMed
28283245	RESULT	1	PubMed
25558198	RESULT	1	PubMed
25534062	RESULT	1	PubMed
24266542	RESULT	1	PubMed
21938530	RESULT	1	PubMed

1 to 10 of 27

See all 27 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016642

GET https://conductscience.org/api/diseases/v1/MONDO_0016642/drugs?page=2

API reference For AI assistants